United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

14-17mmhg) below knee open toe lymphoedema garment short size a beige (judd medical ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

14-17mmhg) below knee open toe lymphoedema garment short size b beige (judd medical ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

14-17mmhg) below knee open toe lymphoedema garment short size c beige (judd medical ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

14-17mmhg) below knee open toe lymphoedema garment short size d beige (judd medical ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

14-17mmhg) below knee open toe lymphoedema garment short size e beige (judd medical ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

14-17mmhg) below knee open toe lymphoedema garment short size f beige (judd medical ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

14-17mmhg) below knee open toe lymphoedema garment short size g beige (judd medical ltd -

United States - English - NLM (National Library of Medicine)

morkin companies, inc dba medical technologies, inc - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide tablets are particularly useful when an agent with greater diuretic potential is desired. oral furosemide tablets may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide tablets alone. furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide. in premature infants furosemide tablets may precipitate nephrocalcinosis/nephrolithiasis. nephrocalcinosis/ nephrolithiasis has also been observed in children under 4 years of age with no history of prematurity who have been treated chronically with furosemide tablets. monitor renal functi

United States - English - NLM (National Library of Medicine)

jubilant cadista pharmaceuticals inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila, or mycoplasma pneumoniae [see dosage and administration (2.1) and clinical studies (14.2)] .   mdr

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)]. levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiell